Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project PharmaTimesQuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billionNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) PharmaTimes QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot programNext: Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal Related Stories Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026
